Lanraplenib

CAS No. 1800046-95-0

Lanraplenib( GS-9876 )

Catalog No. M23810 CAS No. 1800046-95-0

Lanraplenib is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 61 In Stock
5MG 91 In Stock
10MG 153 In Stock
25MG 275 In Stock
50MG 408 In Stock
100MG 600 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lanraplenib
  • Note
    Research use only, not for human use.
  • Brief Description
    Lanraplenib is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
  • Description
    Lanraplenib is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GS-9876
  • Pathway
    Angiogenesis
  • Target
    Syk
  • Recptor
    SYK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1800046-95-0
  • Formula Weight
    443.5
  • Molecular Formula
    C23H25N9O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:41.67 mg/mL (93.96 mM; Need ultrasonic)
  • SMILES
    C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Di Paolo J, et al. FRI0049 Preclinical Characterization of GS-9876, A Novel, Oral SYK Inhibitor That Shows Efficacy in Multiple Established Rat Models of Collagen-Induced Arthritis.Annals of the Rheumatic Diseases 2016;75:443-444.
molnova catalog
related products
  • Lanraplenib

    Lanraplenib is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.

  • SecinH3

    SecinH3 is selective cytohesin inhibitor.

  • Amylmetacresol

    Amylmetacresol is used in the treatment of sore throat or ‘acute sore throat’, pharyngitis, tonsillitis and laryngitis. As well as in the treatment of influenza A and SARS-CoV.